United Therapeutics (UTHR)
NASDAQ:UTHR
Top Page
United Therapeutics
(NASDAQ:UTHR)
Select Model
Select Model
Rating:84Outperform
Price Target:
$613.00
▲(6.12% Upside)
Action:ReiteratedDate:03/31/26
Score is driven primarily by standout financial quality (strong growth, very high margins, and a debt-free balance sheet) and supported by positive earnings-call outlook plus multiple favorable clinical and capital-allocation catalysts. Technicals are constructive but not strongly overbought, while valuation is reasonable rather than deeply discounted and lacks dividend yield support.
Positive Factors
Cash generation
Consistent, sizable operating cash flow and multi-year free cash flow provide durable funding for R&D, near-term commercial launches, and capital returns. This reduces dependence on external financing and supports execution on pipeline milestones and strategic buybacks over the next 2–6 months and beyond.
Negative Factors
Binary trial dependency
Key near-term growth and filings depend on binary clinical readouts and regulatory decisions. Successful unblindings are required to realize forecasted launches; failures or delays would materially reduce projected revenue and defer commercialization, creating execution risk over the next 2–18 months.
Read all positive and negative factors
Positive Factors
Negative Factors
Cash generation
Consistent, sizable operating cash flow and multi-year free cash flow provide durable funding for R&D, near-term commercial launches, and capital returns. This reduces dependence on external financing and supports execution on pipeline milestones and strategic buybacks over the next 2–6 months and beyond.
Read all positive factors
United Therapeutics (UTHR) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$25.06B
Dividend YieldN/A
Average Volume (3M)639.80K
Price to Earnings (P/E)16.2
Beta (1Y)0.52
Revenue Growth13.50%
EPS Growth17.16%
CountryUS
Employees1,305
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)7.70
Shares Outstanding43,827,686
10 Day Avg. Volume743,510
30 Day Avg. Volume639,805
Financial Highlights & Ratios
PEG Ratio1.16
Price to Book (P/B)3.04
Price to Sales (P/S)6.78
P/FCF Ratio20.74
Enterprise Value/Market Cap0.95
Enterprise Value/Revenue7.47
Enterprise Value/Gross Profit8.49
Enterprise Value/Ebitda13.15
Forecast
1Y Price Target
$635.62Price Target Upside10.04% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering14
EPS Forecast (FY)29.44
Revenue Forecast (FY)$3.30B
United Therapeutics Business Overview & Revenue Model
Company Description
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and international...
How the Company Makes Money
United Therapeutics primarily makes money by selling prescription pharmaceuticals, with the majority of revenue coming from its commercial PAH franchise. Key revenue streams include net product sales of PAH therapies such as treprostinil-based pro...
United Therapeutics Key Performance Indicators (KPIs)
Any
Revenue by Geography
Breaks down revenue across different regions, revealing where the company is strongest and where it may face risk or growth potential due to local economic conditions or market share shifts.
Breaks down revenue across different regions, revealing where the company is strongest and where it may face risk or growth potential due to local economic conditions or market share shifts.
Data provided by:
The Fly
The FlyUnited Therapeutics Earnings Call Summary
Earnings Call Date:Feb 25, 2026
(Q4-2025)
| % Change Since: |
Next Earnings Date:May 06, 2026
Earnings Call Sentiment Positive
The call conveyed a broadly positive outlook driven by record 2025 revenue (>$3B), double-digit growth, strong Tyvaso performance (Q4 Tyvaso +12%, Tyvaso DPI +24%), near-term product filings and unblindings, and multiple transformative pipeline programs (Tresmi, super prostacyclin, IPF, transplant initiatives). Management acknowledged short-term variability in patient starts, distributor ordering seasonality, and emerging competition from Liquidia/Yutrepia. Key near-term catalysts are binary (trial unblindings and regulatory approvals), creating upside if positive but presenting execution risk if delayed or unsuccessful.Positive Updates
Record Annual Revenue and Growth
Full-year 2025 total revenue surpassed $3.0 billion for the first time in company history, representing 11% growth versus full-year 2024.
Negative Updates
Short-Term Patient Starts Lagging
Patient starts have lagged behind referral trends; management attributes this to Q4 seasonality and severe weather in January, although recent weeks in February show improvement.
Read all updates
Q4-2025 Updates
Positive
Negative
Record Annual Revenue and Growth
Full-year 2025 total revenue surpassed $3.0 billion for the first time in company history, representing 11% growth versus full-year 2024.
Read all positive updates
Company Guidance
Management reiterated guidance for durable double‑digit revenue growth, reporting FY2025 total revenue topping $3.0 billion (first time) with 11% full‑year growth vs. 2024, Q4 revenue of $790 million (+7% YoY), and Tyvaso Q4 revenue of $464 million (+12% YoY) driven by Tyvaso DPI which grew 24% YoY; they noted referral rates through mid‑February were the highest in two years (3 of the last 4 months at or above pre‑competitive‑launch levels) and expect sequential revenue growth to resume by Q2. Management confirmed product milestones and timelines: aim for a $4.0 billion revenue run‑rate (~$1.0 billion/quarter) by the back half of 2027, three planned commercial launches tied to 2027 (a once‑daily “super prostacyclin” with unblinding next week, a cough‑reducing soft‑mist inhaler “Tresmi” to be filed this year and launched next year—human studies show up to 90% cough reduction—and Tyvaso IPF with a second pivotal unblinding next month after TETON‑2 showed a +95.6 mL absolute FVC benefit; if confirmed, filing and commercial launch into IPF by no later than June 2027). They also updated transplant programs: Xeno has 2 patients transplanted with a 6‑patient cohort expected by summer and registration activity in 2027 (commercial target 2030), and Miromatrix has fully enrolled its first manufactured liver trial with FDA guidance expected this year.United Therapeutics Financial Statement Overview
Summary
Income Statement
92
Very Positive
Balance Sheet
95
Very Positive
Cash Flow
86
Very Positive
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 3.18B | 2.88B | 2.33B | 1.94B | 1.69B |
| Gross Profit | 2.80B | 2.57B | 2.07B | 1.79B | 1.56B |
| EBITDA | 1.82B | 1.65B | 1.39B | 1.04B | 736.80M |
| Net Income | 1.33B | 1.20B | 984.80M | 727.30M | 475.80M |
Balance Sheet | |||||
| Total Assets | 7.88B | 7.36B | 7.17B | 6.04B | 5.17B |
| Cash, Cash Equivalents and Short-Term Investments | 1.56B | 3.27B | 2.99B | 2.84B | 1.93B |
| Total Debt | 0.00 | 300.00M | 700.00M | 800.00M | 800.00M |
| Total Liabilities | 783.80M | 920.00M | 1.18B | 1.25B | 1.21B |
| Stockholders Equity | 7.10B | 6.44B | 5.98B | 4.80B | 3.96B |
Cash Flow | |||||
| Free Cash Flow | 1.04B | 1.08B | 747.60M | 663.70M | 477.40M |
| Operating Cash Flow | 1.56B | 1.33B | 978.00M | 802.50M | 598.20M |
| Investing Cash Flow | -551.30M | 417.20M | -719.60M | -811.50M | -486.90M |
| Financing Cash Flow | -1.15B | -1.25B | -11.90M | 75.40M | 44.80M |
United Therapeutics Technical Analysis
Positive
577.63
Price Trends
514.65
Positive
500.46
Positive
434.19
Positive
Market Momentum
17.42
Negative
59.56
Neutral
55.95
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For UTHR, the sentiment is Positive. The current price of 577.63 is above the 20-day moving average (MA) of 550.60, above the 50-day MA of 514.65, and above the 200-day MA of 434.19, indicating a bullish trend. The MACD of 17.42 indicates Negative momentum. The RSI at 59.56 is Neutral, neither overbought nor oversold. The STOCH value of 55.95 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for UTHR.
United Therapeutics Risk Analysis
United Therapeutics disclosed 32 risk factors in its most recent earnings report. United Therapeutics reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
United Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
84 Outperform | $25.06B | 16.17 | 19.30% | ― | 13.50% | 17.16% | |
76 Outperform | $11.50B | 12.10 | 36.88% | ― | 9.93% | 54.33% | |
74 Outperform | $19.12B | 14.98 | 29.15% | ― | 18.09% | 3563.21% | |
68 Neutral | $10.49B | 32.67 | 5.82% | ― | 12.31% | 60.21% | |
66 Neutral | $17.36B | 19.86 | 18.99% | ― | 24.98% | 127.06% | |
57 Neutral | $14.69B | -50.22 | 127.54% | ― | 103.32% | 47.55% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
UTHR
United Therapeutics
577.63
293.32
103.17%
BMRN
BioMarin Pharmaceutical
54.88
-4.79
-8.03%
EXEL
Exelixis
44.96
9.22
25.80%
INCY
Incyte
95.55
36.33
61.35%
ASND
Ascendis Pharma
248.55
93.05
59.84%
GMAB
Genmab
28.20
8.88
45.96%
United Therapeutics Corporate Events
Business Operations and StrategyProduct-Related Announcements
United Therapeutics’ Tyvaso Shows Pivotal Success in IPF
Positive
Mar 30, 2026
On March 30, 2026, United Therapeutics reported that its 598-patient phase 3 TETON-1 trial of nebulized Tyvaso in idiopathic pulmonary fibrosis met its primary endpoint, showing a 130.1 mL advantage in forced vital capacity over placebo at 52 week...
Business Operations and StrategyStock Buyback
United Therapeutics Launches Major Accelerated Share Repurchase Program
Positive
Mar 9, 2026
United Therapeutics’ board on March 8, 2026 authorized a new stock repurchase program of up to $2 billion through March 9, 2027, signaling confidence in the company’s growth prospects and cash-flow trajectory. Management framed the mov...
Business Operations and StrategyProduct-Related Announcements
United Therapeutics’ Ralinepag Trial Success Boosts PAH Outlook
Positive
Mar 2, 2026
On March 2, 2026, United Therapeutics reported that its pivotal phase 3 ADVANCE OUTCOMES trial of ralinepag in pulmonary arterial hypertension met its primary endpoint, cutting the risk of clinical worsening events by 55% versus placebo and showin...
Business Operations and StrategyExecutive/Board Changes
United Therapeutics appoints new director, updates bylaws
Positive
Jan 22, 2026
On January 21, 2026, United Therapeutics’ board expanded its size to 13 members and appointed Kevin J. Tracey, M.D., a prominent researcher and biotech entrepreneur in inflammation and bioelectronic medicine, as a new director, granting him ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.